Medicinal composition for treating osteoporosis and preparation method thereof
A technology for osteoporosis and composition, which is applied in the field of pharmaceutical preparations for treating osteoporosis and its preparation, can solve problems such as side effects, and achieve the effects of controllable quality, convenient administration, and mature extraction and molding processes
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0019] Embodiment 1: the preparation of pharmaceutical composition of the present invention
[0020] Soak Epimedium 250g, Eucommia ulmoides (salt broiled) 160g, Dipsacus 160g, Astragalus 200g, natural copper (calcined) 80g, Trichosanthes 160g in water, decoct three times for 1.5 hours each time, filter, combine the filtrates, and concentrate to 1ml The clear ointment equivalent to 1.25g of crude drug is allowed to cool, and ethanol is added until the alcohol content is 60%, left to stand overnight, and filtered to obtain alcohol precipitated liquid. 150 g of psoraleae and 150 g of Achyranthes bidentata were extracted twice with 60% ethanol under reflux for 1.5 hours each time, filtered, and the filtrates were combined to obtain an alcohol extract. The alcohol precipitation solution is combined with the alcohol extraction solution, and the ethanol is recovered and concentrated to an extract of the extract with a relative density of 1.25-1.30 (60° C.). 80 g of Astragalus membra...
Embodiment 2
[0021] Embodiment 2: the pharmacodynamics test of pharmaceutical composition of the present invention
[0022] (1) Impact on experimental osteoporosis rats: the rat model of osteoporosis induced by ovariectomy and testicular removal was adopted, and the pharmaceutical composition of the present invention was given by intragastric administration for 90 days after the operation, and the relative Blood indexes, bone tissue morphomechanical parameters and bone tissue ultrastructure were set up as positive drug group and normal saline group. Results: After treatment, the pharmaceutical composition of the present invention can significantly increase the bone density of rats, increase the dry weight of the femur and bone calcium content, increase the bone mass, and have biphasic pharmacological effects of inhibiting bone resorption and promoting bone formation. Ultrastructural observation showed that after the model mice took the drug, the activity of bone cells gradually shifted fro...
Embodiment 3
[0026] Embodiment 3: Toxicological research of pharmaceutical composition of the present invention
[0027] (1) Acute toxicity test: the toxicity of the pharmaceutical composition of the present invention is very small, and the mice are administered intragastrically with the maximum dosage volume and the highest dosage concentration, and are continuously observed for 14 days. The results showed that the animals showed a decrease in activity, and then gradually returned to normal. After about 24 hours, the behavior and activities basically returned to normal; no animal died. During the observation period of 14 days after administration, the weight gain was normal, and no obvious abnormal symptoms were seen. Rats were gavaged with the maximum administration capacity and the highest drug concentration, and were continuously observed for 14 days after administration. Results No obvious abnormal reaction was found in all animals, and no animal died. During the 14-day observation ...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com